Published in Arch Neurol on May 01, 1999
Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Arch Neurol (1999) 2.42
Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry (2007) 5.49
Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology (1990) 4.41
Huntington disease: clinical care and evaluation. Neurology (1979) 3.54
Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology (2000) 2.49
Homozygotes for Huntington's disease. Nature (1987) 2.40
Alzheimer's disease and its Lewy body variant: a clinical analysis of postmortem verified cases. Am J Psychiatry (1996) 2.30
Clinical markers of early disease in persons near onset of Huntington's disease. Neurology (2001) 2.11
On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology (1975) 1.96
Weight loss in early stage of Huntington's disease. Neurology (2002) 1.79
Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord (1990) 1.76
Vasoactive intestinal polypeptide: abundant immunoreactivity in neural cell lines and normal nervous tissue. Science (1976) 1.76
DNA-triplet repeats and neurologic disease. N Engl J Med (1996) 1.60
Competent patients with advanced states of permanent paralysis have the right to forgo life-sustaining therapy. Neurology (1993) 1.58
Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology (1981) 1.57
Familial opticoacoustic nerve degeneration and polyneuropathy. Neurology (1967) 1.50
Category fluency in mild cognitive impairment: reduced effect of practice in test-retest conditions. Alzheimer Dis Assoc Disord (2004) 1.48
Huntington's disease in Venezuela: neurologic features and functional decline. Neurology (1986) 1.39
Psychiatric syndromes in Huntington's disease. Am J Psychiatry (1983) 1.38
Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin Pharmacol Ther (1999) 1.35
Peripheral neuropathy and starvation after gastric partitioning for morbid obesity. Ann Intern Med (1982) 1.31
Atrophy of medium spiny I striatal dendrites in advanced Parkinson's disease. Brain Res (1988) 1.28
Correlation of double-minute chromosomes with unstable multidrug cross-resistance in uptake mutants of neuroblastoma cells. Proc Natl Acad Sci U S A (1981) 1.28
Autosomal dominant striatonigral degeneration. A clinical, pathologic, and biochemical study of a new genetic disorder. Neurology (1976) 1.27
Markers for gene expression in cultured cells from the nervous system. J Biol Chem (1972) 1.26
Transverse myelitis associated with heroin addiction. JAMA (1968) 1.22
NMDA receptor losses in putamen from patients with Huntington's disease. Science (1988) 1.21
Autosomal dominant cerebellar phenotypes: the genotype has settled the issue. Neurology (1995) 1.21
Effects of practice on category fluency in Alzheimer's disease. Clin Neuropsychol (2001) 1.20
Apoptosis and neurologic disease. Am J Med (2000) 1.17
Clinical-pathologic correlation in Huntington's disease: a neuropsychological and computed tomography study. Neurology (1989) 1.14
Erratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian mobility. Neurology (1988) 1.13
Mononeuritis multiplex in lepromatous leprosy. Arch Neurol (1968) 1.12
Predictors of nursing home placement in Huntington disease. Neurology (2003) 1.11
Huntington's disease: treatment with dipropylacetic acid and gamma-aminobutyric acid. Neurology (1976) 1.11
Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol (1986) 1.08
Heterogeneous dopamine receptor changes in early and late Huntington's disease. Neurosci Lett (1991) 1.07
Neurologic involvement in Urbach-Wiethe's disease (lipoid proteinosis). A clinical, ultrastructural, and chemical study. Neurology (1971) 1.07
Neuroleptic malignant syndrome. Clin Neuropharmacol (1984) 1.07
Functional decline in Huntington's disease. Mov Disord (1995) 1.04
Platelet APP isoform ratios correlate with declining cognition in AD. Neurology (2000) 1.01
Olivopontocerebellar degeneration. Clinical and ultrastructural abnormalities. Arch Neurol (1974) 1.01
Comparison of the hopkins verbal learning test-revised to the California verbal learning test in Alzheimer's disease. Appl Neuropsychol (2001) 1.00
Neurological complications of fibrous dysplasia of the skull. Arch Neurol (1968) 0.99
Alterations in L-glutamate binding in Alzheimer's and Huntington's diseases. Science (1985) 0.98
Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants. Neurology (2009) 0.98
Parotid and whole saliva in the prediction of serum total and free phenytoin concentrations. Clin Pharmacol Ther (1978) 0.97
Joseph's disease: an autosomal dominant neurological disease in the Portuguese of the United States and the Azores Islands. Adv Neurol (1978) 0.97
The natural history of Machado-Joseph disease. An analysis of 138 personally examined cases. Can J Neurol Sci (1984) 0.97
Creatine kinase BB isoenzyme levels by radioimmunoassay in patients with neurological disease. Ann Neurol (1978) 0.97
A prospective evaluation of cognitive decline in early Huntington's disease: functional and radiographic correlates. Neurology (1995) 0.95
Glial tumor metastases through a ventriculo-pleural shunt. Resultant massive pleural effusion. Arch Neurol (1968) 0.94
The Machado-Joseph disease locus is different from the spinocerebellar ataxia locus (SCA1). Genomics (1992) 0.94
Huntington's disease. A decade of progress. Neurol Clin (1984) 0.93
Neural transplantation: a call for patience rather than patients. Science (1988) 0.93
Familial Tourette's syndrome: report of a large pedigree and potential for linkage analysis. Neurology (1986) 0.92
Case 1, 1989: juvenile-onset parkinsonism, dystonia, and pyramidal tract signs. Mov Disord (1989) 0.91
Vasoactive intestinal polypeptide in brain synaptosomes. Lancet (1976) 0.91
Apolipoprotein E epsilon 4, other risk factors, and course of Alzheimer's disease. Biol Psychiatry (1999) 0.91
Prion proteins: a biological role beyond prion diseases. Acta Neurol Scand (2007) 0.90
Progressive ophthalmoplegia. Report of cases. Arch Neurol (1968) 0.90
Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia. Ann Neurol (1988) 0.90
Joseph disease: an autosomal dominant motor system degeneration. Adv Neurol (1984) 0.90
Studies with bromocriptine: III. Concomitant administration of caffeine to patients with idiopathic parkinsonism. Neurology (1976) 0.89
Some therapeutic observations in Wilson's disease. Adv Neurol (1983) 0.89
Severity of Tourette's syndrome in one large kindred. Implication for determination of disease prevalence rate. Arch Neurol (1987) 0.89
Benzodiazepine and GABA receptors in early Huntington's disease. Neurology (1984) 0.89
Differences in the distribution of poly(A) size classes in individual messenger RNAs from neuroblastoma cells. J Biol Chem (1979) 0.89
Neurodegenerative disorders and aging. Alzheimer's disease and Parkinson's disease--common ground. Ann N Y Acad Sci (1988) 0.88
Myoclonus and dystonia: a family study. Adv Neurol (1988) 0.88
Physiology of glia: glial-neuronal interactions. Int Rev Neurobiol (1979) 0.88
Knowledge of the Genetic Information Nondiscrimination act among individuals affected by Huntington disease. Clin Genet (2012) 0.87
Long-term experience with pergolide therapy of advanced parkinsonism. Neurology (1985) 0.87
Frontal lobe ataxia. Surg Neurol (1995) 0.87
Experimental chemotherapy of neuroblastoma. II. Increased thymidylate synthetase activity in a 5-fluorodeoxyuridine-resistant variant of mouse neuroblastoma. Mol Pharmacol (1975) 0.86
Bromocriptine inhibits norepinephrine release. Clin Pharmacol Ther (1979) 0.86
Huntington's disease. Annu Rev Med (1975) 0.85
Caffeine and the antiparkinsonian response to levodopa or piribedil. Neurology (1975) 0.85
Dementia in Huntington disease: a cross-sectional analysis of intellectual decline. Adv Neurol (1983) 0.85
A radioisotopic, chromatographic microassay for acetyl-coenzyme A synthetase and some preliminary studies on the rat brain enzyme. Biochim Biophys Acta (1973) 0.85
Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients. Neurology (2003) 0.85
Duodenal and gastric delivery of levodopa in parkinsonism. Ann Neurol (1988) 0.84
Autosomal dominant progressive syndrome of motor-speech loss without dementia. Neurology (1997) 0.84
Carbamazepine-induced tics. Clin Neuropharmacol (1989) 0.84
Coexistence of Huntington's disease and familial amyotrophic lateral sclerosis: case presentation. Acta Neuropathol (1996) 0.84
A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord (1994) 0.84
Altered apolipoprotein E secretion in cytokine treated human astrocyte cultures. J Neurol Sci (1997) 0.84
Induction of adenosine 3',5'-monophosphate binding proteins by N6,O2'-dibutyryladenosine 3',5'-monophosphate in mouse neuroblastoma cells. Analysis by two-dimensional gel electrophoresis. Biochemistry (1979) 0.84
A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology (2001) 0.84
Glutamate and malate dehydrogenase activities in Joseph disease and olivopontocerebellar atrophy. Neurology (1987) 0.83
Serum antibodies to cytomegalovirus in myasthenia gravis: effects of thymectomy and steroids. Neurology (1978) 0.83
Letter: Fenfluramine and dyskinesias. N Engl J Med (1974) 0.83
A controlled trial of fluoxetine in nondepressed patients with Huntington's disease. Mov Disord (1997) 0.83
Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov Disord (1996) 0.83
Familial paroxysmal dystonic choreoathetosis: a family study. Mov Disord (1987) 0.83
Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci (2006) 0.82
Specific messenger RNA changes in Joseph disease cerebella. Ann Neurol (1983) 0.82
Regulation of the synthesis of choline-O-acetyltransferase and thymidylate synthetase in mouse neuroblastoma in cell culture. Proc Natl Acad Sci U S A (1971) 0.82
Huntington's disease: treatment with muscimol, a GABA-mimetic drug. Ann Neurol (1978) 0.82
Machado Joseph disease maps to the same region of chromosome 14 as the spinocerebellar ataxia type 3 locus. J Med Genet (1995) 0.82
An ergot derivative in the treatment of Parkinson's disease. Postgrad Med J (1976) 0.81